AR111487A1 - Métodos para predecir la falta de respuesta a un tratamiento anti-tnf en sujetos con enfermedad inflamatoria intestinal - Google Patents

Métodos para predecir la falta de respuesta a un tratamiento anti-tnf en sujetos con enfermedad inflamatoria intestinal

Info

Publication number
AR111487A1
AR111487A1 ARP180101019A ARP180101019A AR111487A1 AR 111487 A1 AR111487 A1 AR 111487A1 AR P180101019 A ARP180101019 A AR P180101019A AR P180101019 A ARP180101019 A AR P180101019A AR 111487 A1 AR111487 A1 AR 111487A1
Authority
AR
Argentina
Prior art keywords
subject
nucleobase
level
detected
sample obtained
Prior art date
Application number
ARP180101019A
Other languages
English (en)
Inventor
Dalin Li
Stephan Targan
Dermot Mgovern
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of AR111487A1 publication Critical patent/AR111487A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Métodos para identificar sujetos que no responden a una terapia anti-TNF. Además, un método para seleccionar una terapia para un sujeto con enfermedad inflamatoria intestinal (IBD), y aplicación del tratamiento a dicho sujeto. Reivindicación 1: Un método para tratar un sujeto con una enfermedad o condición inflamatoria, o enfermedad fibroestenótica y/o fibrótica, caracterizado porque comprende administrarle al sujeto una cantidad terapéuticamente eficaz de un agente terapéutico, con la condición de que se detecta un nivel de anticuerpo citoplasmático antineutrófilos (ANCA), o una presencia de una variante de riesgo genético que comprende un alelo de riesgo en la nucleobase 256 en rs5745994 de un locus génico TNFRSF1B, o una combinación de los mismos, en una muestra biológica obtenida del sujeto. Reivindicación 2: El método de la reivindicación 1, caracterizado porque se detecta un nivel disminuido de TNFR2 en una muestra obtenida del sujeto, en comparación con un valor de referencia obtenido de un individuo que no es un portador de la variante de riesgo genético. Reivindicación 10: El método de la reivindicación 1, caracterizado porque la variante de riesgo genético se detecta al poner en contacto la muestra biológica obtenida del sujeto con una secuencia de ácido nucleico con capacidad de hibridizar con 10 nucleobases contiguas de SEQ ID Nº 1 que abarcan la nucleobase 256 en condiciones de hibridización estándares. Reivindicación 12: El método caracterizado porque comprende: realizar un ensayo para detectar en una muestra biológica obtenida de un sujeto con una enfermedad o condición inflamatoria, o enfermedad fibroestenótica y/o fibrótica un nivel de anticuerpos citoplasmáticos antineutrófilos (ANCA), una presencia de una variante de riesgo genético que comprende un alelo de riesgo en la nucleobase 256 en rs5745994 de un locus génico TNFRSF1B, o una combinación de los mismos; identificar al sujeto como no respondedor a la terapia con anti-TNF, o susceptible a no responder a la terapia con anti-TNF, con la condición de que se detecte (i) un nivel de ANCA que está en un primer nivel umbral que comprende aproximadamente 100 unidades de ELISA (EU) o por encima del mismo, o (ii) un nivel de ANCA que es menor que el primer nivel umbral y mayor que un segundo nivel umbral que comprende aproximadamente 50 EU, y la presencia de la variante de riesgo genético, en la muestra biológica obtenida del sujeto. Reivindicación 19: Un kit caracterizado porque comprende una composición que comprende por lo menos 10, pero menos de 50 residuos de nucleobases contiguas de SEQ ID Nº 1, en donde los residuos de nucleobases contiguas comprenden la nucleobase en la posición 256 en rs5745994 (SEQ ID Nº 1), y en donde los residuos de nucleobases contiguas están conectados a una molécula que puede detectarse que comprende un fluoróforo, y un par de cebadores configurados para hibridizar con 10 nucleobases contiguas de SEQ ID Nº 1 que abarcan la nucleobase 256.
ARP180101019A 2017-04-20 2018-04-20 Métodos para predecir la falta de respuesta a un tratamiento anti-tnf en sujetos con enfermedad inflamatoria intestinal AR111487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487971P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
AR111487A1 true AR111487A1 (es) 2019-07-17

Family

ID=63853028

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101019A AR111487A1 (es) 2017-04-20 2018-04-20 Métodos para predecir la falta de respuesta a un tratamiento anti-tnf en sujetos con enfermedad inflamatoria intestinal

Country Status (4)

Country Link
US (3) US10626180B2 (es)
AR (1) AR111487A1 (es)
TW (1) TW201842191A (es)
WO (1) WO2018195328A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
KR101982899B1 (ko) 2011-09-30 2019-05-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 ＴＬ1ａ에 대한 항체 및 그의 용도
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
KR20240095481A (ko) 2016-03-17 2024-06-25 세다르스-신나이 메디칼 센터 Rnaset2를 통한 염증성 장 질환의 진단 방법
MX392069B (es) * 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
WO2018195328A1 (en) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease
US12264368B2 (en) 2018-07-06 2025-04-01 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
WO2020112890A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
WO2020163713A1 (en) * 2019-02-08 2020-08-13 Cedars-Sinai Medical Center Methods, systems, and kits for treating inflammatory disease targeting skap2
AU2020275413A1 (en) 2019-05-14 2021-12-23 Cedars-Sinai Medical Center TL1A patient selection methods, systems, and devices
TW202600603A (zh) * 2019-10-24 2026-01-01 美商普羅米修斯生物科學股份有限公司 針對類-tnf配體1a (tl1a)之人類化抗體及其用途
NZ787680A (en) 2019-10-24 2026-02-27 Cedars Sinai Medical Center Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
CA3180632A1 (en) * 2020-06-03 2021-12-09 Cedars-Sinai Medical Center Methods and systems for measuring post-operative disease recurrence
AU2021377688A1 (en) * 2020-11-13 2023-06-29 Cedars-Sinai Medical Center Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
MX2023009681A (es) * 2021-02-18 2023-10-30 Prometheus Biosciences Inc Composiciones de anticuerpos anti-tl1a y metodos de tratamiento en el pulmon.
WO2023034111A1 (en) * 2021-08-30 2023-03-09 Inflammatix, Inc. A baseline gene expression-based prognostic for anti-tnf alpha therapy response in patients with inflammatory bowel disease
CN119948058A (zh) * 2022-07-25 2025-05-06 普罗米修斯生物科学公司 抗cd30l抗体、其制剂及其用途
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874233A (en) * 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
ES2445892T3 (es) * 2008-08-25 2014-03-05 Janssen Biotech, Inc. Biomarcadores para el tratamiento anti-TNF en colitis ulcerosa y trastornos relacionados
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
WO2018195328A1 (en) 2017-04-20 2018-10-25 Cedars-Sinai Medical Center Methods of predicting non-response to anti-tnf treatment in subjects with inflammatory bowel disease

Also Published As

Publication number Publication date
US11180565B2 (en) 2021-11-23
US20220153855A1 (en) 2022-05-19
US12018086B2 (en) 2024-06-25
US20180305459A1 (en) 2018-10-25
TW201842191A (zh) 2018-12-01
WO2018195328A1 (en) 2018-10-25
US20200231690A1 (en) 2020-07-23
US10626180B2 (en) 2020-04-21

Similar Documents

Publication Publication Date Title
AR111487A1 (es) Métodos para predecir la falta de respuesta a un tratamiento anti-tnf en sujetos con enfermedad inflamatoria intestinal
US10144975B2 (en) Anellovirus genome quantification as a biomarker of immune suppression
Andrade et al. Trypanosoma cruzi: role of host genetic background in the differential tissue distribution of parasite clonal populations
JP2017184642A (ja) 認知症マーカー、それを用いた認知症の評価方法、評価試薬および評価キット
Weerasooriya et al. Epidemiology of bovine hemoprotozoa parasites in cattle and water buffalo in Vietnam
Marfell et al. Global gene expression profiling of monocyte-derived macrophages from red deer (Cervus elaphus) genotypically resistant or susceptible to Mycobacterium avium subspecies paratuberculosis infection
Pan et al. Analysis of immune-related gene expression in chicken peripheral blood mononuclear cells following Salmonella enterica serovar Enteritidis infection in vitro
Cremonesi et al. Identification of Prototheca species from bovine milk samples by PCR-single strand conformation polymorphism
Matsui et al. High level of IL-10 expression in the blood of animal models possibly relates to resistance against leptospirosis
Ishii et al. Diagnosis of resistance alleles in codon 167 of the beta-tubulin (Cya-tbb-1) gene from third-stage larvae of horse cyathostomins
Eraky et al. Predominance of Cryptosporidium parvum genotype among diarrheic children from Egypt as an indicator for zoonotic transmission
Poonsuk et al. Detection of the mex efflux pumps in Pseudomonas aeruginosa by using a combined resistance-phenotypic markers and multiplex RT-PCR
WO2015149720A1 (en) Hnf4g-rspo2 fusion gene and use thereof in treatment of cancer
Mercier et al. Assessment of Toll-like receptor 2, 4 and 9 SNP genotypes in canine sino-nasal aspergillosis
Gossner et al. Expression of sheep interleukin 23 (IL23A, alpha subunit p19) in two distinct gastrointestinal diseases
Castillo-Ureta et al. First report of autochthonous canine leishmaniasis caused by Leishmania (L.) mexicana in Sinaloa, Mexico
Wilkie et al. Variations in T cell transcription factor sequence and expression associated with resistance to the sheep nematode Teladorsagia circumcincta
Roudbary et al. Relation of ALS 1 and ALS3 genes and fluconazole resistance in Candida albicans isolated from vaginal candidacies
RU2016138574A (ru) Способ лечения депрессии и депрессивного эпизода тяжелой степени
KR101514431B1 (ko) 드렁허리 토속종 판별용 단일염기다형 유전자 마커 및 그를 이용한 방법
JP2016523103A5 (es)
Kishimoto et al. 26S rDNA-based phylogenetic investigation of Japanese cattle-associated Prototheca zopfii isolates
Abdulwahhab Phylogenetic tree of Blastocystis hominis in Iraqi children in Salah AL-Deen province, Iraq
WO2009045172A1 (en) Method and/or kit for determining response to muscarinic receptor antagonist treatment
Maeda et al. Molecular cloning and expression analysis of the canine chemokine receptor CCR9

Legal Events

Date Code Title Description
FB Suspension of granting procedure